6533b7defe1ef96bd1276c00
RESEARCH PRODUCT
Discontinuation of treatment with Natalizumab after 24 courses. Report from spontaneous, observational, prospective study (TYSTOP).
M ClericoS De MercantiF PiazzaE VersinoD GnedM GibbinV Brescia MorraR LanzilloL AmatoM QuarantelliA GhezziA BianchiD BaronciniMt FerròF VitettaM D’onghiaD PaolicelliM TrojanoDurelli L.Giuseppe SalemiSabrina Realmutosubject
Multiple Sclerosis Natalizumab TySTOPSettore MED/26 - Neurologiayear | journal | country | edition | language |
---|---|---|---|---|
2013-01-01 |